BioCentury | Nov 14, 2020
Product Development

Complete response for Sanofi’s rare anemia candidate; plus Sumitovant-Urovant, C4-Roche, IN8bio and Synendos

...reuptake inhibitors to treat CNS disorders associated with anxiety, mood and stress-related disorders. BC Staff sutimlimab (BIVV009, tnt009) Sanofi Complement...
BioCentury | Jan 22, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...to SEK135.70 on Monday. Sanofi and Bioverativ expect their deal to close within three months. Jennie Walters ALN-AT3 Alprolix BIVV009 Eloctate fitusiran SAR439774 TNT009 Alnylam...
BioCentury | May 26, 2017
Company News

Bioverativ aquiring True North

...North Therapeutics Inc. (South San Francisco, Calif.). The deal gives Bioverativ rights to True North's TNT009...
...shareholders will receive $400 million up front and are eligible for $425 million in milestones. TNT009...
...TNT009 could "move quickly into a registrational trial." In the Phase Ib trial, Bioverativ said TNT009...
BioCentury | May 26, 2017
Finance

Fast cash

...exclude True North's undisclosed cash. Triggers for the milestones are undisclosed. True North’s lead asset, TNT009...
...to treat cold agglutinin disease (CAD). On a conference call, Bioverativ CEO John Cox said TNT009...
...it spun out from Biogen Inc. (NASDAQ:BIIB) in February (see BioCentury, Feb. 10, 2017) . TNT009...
BioCentury | May 23, 2017
Company News

Bioverativ acquiring True North

...North Therapeutics Inc. (South San Francisco, Calif.). The deal gives Bioverativ rights to True North's TNT009...
...shareholders will receive $400 million up front and are eligible for $425 million in milestones. TNT009...
...TNT009 could "move quickly into a registrational trial." In the Phase Ib study, Bioverativ said TNT009...
BioCentury | Oct 31, 2016
Finance

Complement cash

...True North Therapeutics Inc. ’s first clinical data for lead molecule TNT009 convinced new investor HBM...
...meeting in Copenhagen showing that four of five cold agglutinin disease (CAD) patients treated with TNT009...
...of hemoglobin increase convinced HBM to back True North. He added that the firm expects TNT009...
BioCentury | Oct 18, 2016
Financial News

True North raises $45M series D

...Perceptive Advisors. New investor Franklin Templeton Investments and undisclosed existing investors also participated. The company's TNT009...
...North announced interim Phase Ib data that showed three of five CAD patients treated with TNT009...
...meeting in Copenhagen. CEO Nancy Stagliano said the new round will support further development of TNT009...
BioCentury | Jun 20, 2016
Clinical News

TNT009: Interim Phase Ib data

...showed that a single dose of 10 mg/kg IV TNT009 followed by 60 mg/kg IV TNT009...
...patient program and re-exposure to TNT009 again led to remission in each of those patients. TNT009...
...is evaluating a single dose of 10 mg/kg IV TNT009 followed by 60 mg/kg IV TNT009...
BioCentury | Mar 14, 2016
Company News

True North Therapeutics hematology news

...CAD, adding that the disease has a prevalence of about 20 per million. True North’s TNT009...
BioCentury | Dec 4, 2015
Financial News

True North raises $40M series C

...and Baxalta Ventures. This month, True North plans to begin Phase Ib testing of its TNT009...
...to treat cold agglutinin disease (CAD). "There's always been a strong scientific rationale for why TNT009...
Items per page:
1 - 10 of 19